GlassScriptPhysician profile
Chiara Ferrari
NPI 1457627887
$2,702.59
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,725 · 2020: $920 · 2021: $57.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $749.01 | 2019-2020 | |
| Allergan, INC. | $364.69 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $359.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $237.80 | 2019-2020 | |
| Lundbeck LLC | $214.94 | 2019-2020 | |
| Shire North American Group INC | $177.07 | 2019 | |
| Neuronetics, INC. | $146.22 | 2019 | |
| Vanda Pharmaceuticals INC. | $117.97 | 2019 | |
| Eisai INC. | $89.16 | 2020 | |
| Adlon Therapeutics L.P. | $74.16 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $38.76 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $37.40 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.44 | 2020 | |
| Neos Therapeutics, LP | $24.77 | 2020 | |
| Sun Pharmaceutical Industries INC. | $24.62 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $19.71 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chiara Ferrari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.